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SUMMARY. Despite the use of multimodal treatment, survival of esophageal cancer (EC) patients remains poor.
One proposed explanation for the relatively poor response to cytotoxic chemotherapy is intratumor heterogeneity.
The aim was to establish a statistical model to objectively measure intratumor heterogeneity of the proportion of
tumor (IHPoT) and to use this newly developed method to measure IHPoT in the pretreatment biopsies from from
EC patients recruited to the OE02 trial. A statistical mixed effect model (MEM) was established for estimating
IHPoT based on variation in hematoxylin/eosin (HE) stained pretreatment biopsy pieces from the same individual
in 218 OE02 trial patients (103 treated by chemotherapy and surgery (chemo+surgery); 115 patients treated by
surgery alone). The relationship between IHPoT, prognosis, chemotherapy survival benefit, and clinicopathological
variables was assessed. About 97 (44.5%) and 121 (55.5%) ECs showed high and low IHPoT, respectively. There was
no significant difference in IHPoT between surgery (median [range], 0.1637 [0–3.17]) and chemo+surgery (median
[range], 0.1692 [0–2.69]) patients (P= 0.43). Chemo+surgery patients with low IHPoT had a significantly longer
survival than surgery patients (HR= 1.81, 95%CI: 1.20–2.75,P= 0.005). There was no survival difference between
chemo+surgery and surgery patients with high IHPoT (HR= 1.15, 95%CI: 0.72–1.81,P= 0.566). This is the first
study suggesting that IHPoT measured in the pretreatment biopsy can predict chemotherapy survival benefit in EC
patients. IHPoT may represent a clinically useful biomarker for patient treatment stratification. Future studies
should determine if pathologists can reliably estimate IHPoT.
KEY WORDS: esophageal cancer, histological heterogeneity, neoadjuvant chemotherapy, pretreatment biopsy,
proportion of tumor.
INTRODUCTION
Esophageal cancer (EC) is the eighth most common
cancer worldwide with more than 572,000 new cases
and 508,500 deaths in 2018.1 The standard of care for
EC patients with locally advanced resectable disease
is chemotherapy or chemoradiotherapy followed by
surgery.2–5 Despite multimodal treatment, survival
remains poor, with a 3-year overall survival rate
of 39%.6 The recent OE05 trial demonstrated that
intensifying treatment by using three drugs instead of
two or increasing the number of chemotherapy cycles
given preoperatively did not improve EC patient
survival.6
Decisions about EC patient treatment are made at
the time of diagnosis after confirming the presence of
cancer in the endoscopic biopsy and clinical staging of
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the disease. We recently quantified the relative tumor
content (proportion of tumor per area [PoT]) as con-
tinuous measurement values on hematoxylin/eosin
(HE) stained digital slides in the pretreatment
biopsies of EC patients using a well-established
morphometricmethod called point counting andwere
able to demonstrate that PoT can predict survival
benefit from cytotoxic chemotherapy.7 Importantly,
our previous study was the first to show that the
relationship between PoT and chemotherapy benefit
was nonlinear: only patients with a mean PoT of
all tumor containing biopsies between 40% and
70% derived benefit from chemotherapy, whereas
patients with mean PoT <40% or mean PoT >70%
did not benefit from chemotherapy. During this
previous study, we noticed that the PoT value can vary
considerably between biopsy pieces from the same
patient.
Considering that not only the absolute mean PoT
value of all tumor containing biopsies per patient7
but also the difference of the PoT value between
biopsy pieces from the same patient (intratumor
heterogeneity of the proportion of tumor [IHPoT])
might influence chemotherapy survival benefit,
we hypothesized that EC patients with relatively
low IHPoT (e.g. similar PoT values in different
biopsies from the same patient) will have greater
survival benefit from neoadjuvant 5-fluoruracil/
cisplatin chemotherapy compared to those with high
IHPoT.
The current study had two aims: (i) to establish a
statisticalmethod to objectivelymeasure intratumoral
heterogeneity of the proportion of tumor (IHPoT)
and (ii) to use this newly developed method to
determine IHPoT in the pretreatment biopsies from
esophageal cancer patients recruited to theOE02 trial.
The relationship of IHPoT with clinicopathological
variables, 5-year overall survival, and chemotherapy
survival benefit was analyzed.
MATERIAL ANDMETHODS
Study population
The UK Medical Research Council (MRC) OE02
trial randomized 802 patients with locally advanced
resectable esophageal cancer to surgery alone or
2 cycles of 5-Fluorouracil plus cisplatin chemotherapy
followed by surgery.3, 8 Absolute tumor content
per biopsy area (proportion of tumor, PoT) of
each pretreatment biopsy piece was available from
281 OE02 trial patients (140 patients treated with
chemotherapy followed by surgery [chemo+surgery]
and 141 patients treated with surgery alone) from our
previous study.7
The study was approved by the South East
Research Ethics Committee, London, UK, REC
reference: 07/H1102/111.
Calculating intratumoral heterogeneity of the
proportion of tumor
Of the 281 patients with existing pretreatment biopsy
PoT value from our previous study,7 218 patients
(surgery patients n= 115, chemo + surgery patients
n= 103) had PoT values from two or more tumor-
containing biopsies. Although a large number of stud-
ies in the literature use the term ‘tumor heterogeneity’,
it is not clear under what conditions samples/values
from the same tumor should be classified as ‘heteroge-
neous’. We set out to establish a statistical method to
calculate an intratumoral heterogeneity index of PoT
and to explore its predictive and prognostic value in
patients with esophageal cancer recruited to the OE02
trial. The statistical method considers the number of
available biopsy pieces and the percentage of tumor
(PoT) value and calculates an indexwhich is ameasure
of the variation between the PoT values of the biopsy
pieces.
In the field of multilevel data analysis, the mixed
effect model (MEM) has been proposed as an appro-
priate model to analyze different quantities measured
from the same individual,9–11 e.g. in our case the
PoT values from different biopsy pieces of the same
patient. We applied the R package ‘lme4’12,13 to build
the MEM, which provides a value describing the level
of variation (heterogeneity) between PoT values of the
same patient. Theoretically, the obtained heterogene-
ity index can range from zero (no heterogeneity) to
infinity (maximal heterogeneity). Details of the sta-
tistical methodology including data structure can be
found in the supplemental information: Text S1 and
Table S1. The error in estimating the intratumoral het-
erogeneity index of PoT (IHPoT index) using MEM
was measured by performing a simulation study; see
supplemental Text S2 for methodology.
Statistical analyses
Q statistic14 was used to optimize the cutoff point for
the IHPoT index using all patients, with respect to
overall survival calculated from the time of random-
ization to the date of deathwithin the 5-year follow-up
period. Patients were stratified by their IHPoT index
into two groups: high and low IHPoT index. Low
IHPoT index was defined as heterogeneity less than
or equal to the cutoff point.
All other statistical analyses were performed
using R (version 3.5.1). The relationship between
IHPoT index and clinicopathological variables (depth
of invasion [(y)pT], lymph node status [(y)pN]
and (y)pTNM stage [UICC TNM classification
6th edition15], Mandard tumor regression grade,16
histological tumor type, resection margin status, and
tumor location) was assessed using chi-square and
Fisher’s exact tests.
The relationship between IHPoT index and 5-year
overall survival (OS) was analyzed using the Kaplan–
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Fig. 1 Range of intratumoral heterogeneity of the proportion of tumor for patients with different number of biopsy pieces.
Meier method and log–rank statistics. Survival
analyses were performed stratifying patients by
IHPoT index and treatment arm to establish the
predictive and prognostic value of IHPoT index. A
P value of <0.05 was considered significant.
As we previously found that only patients with
a mean absolute biopsy PoT value between 40%
and 70% had a survival benefit from preoperative
chemotherapy, we additionally explored whether the
improved OS in this particular patient subgroup
might be related to the degree of heterogeneity of PoT
between different biopsy pieces from the same patient.
For the patients with low IHPoT index, a multivariate
analysis using Cox model adjusted by age, sex, tumor
location, and histological tumor type was performed.
RESULTS
The median number of biopsy pieces per patient was
3 (range 2–12 pieces). In total, PoT values from 775
individual biopsy pieces from 218 patients were avail-
able for analysis. The majority of patients (n= 77,
35.3%) had two biopsies, 56 (25.7%) patients had 3
biopsies, 40 (18.3%) patients had 4 biopsies, 13 (6%)
patients had 5 biopsies, 16 (7.3%) patients had 6 biop-
sies, and 16 (7.3%) patients had 7 or more biopsies
with PoT (Fig. 1).
The median IHPoT index was 0.1638 (range
0–3.17). Based on Q-statistics (see Material and
Methods), we used a cutoff of 0.2030 for the IHPoT
index to classify the heterogeneity of tumors as high
versus low. Tumors from 97 (44.5%) EC patients (48
[41.7%] surgery patients, 49 [47.6%] chemo+surgery
patients) were classified as high IHPoT (IHPoT index
>0.2030). Tumors from 121 (55.5%) EC patients (67
[58.3%] surgery patients, 54 [52.4%] chemo+surgery
patients) were classified as low IHPoT (IHPoT
index ≤0.2030). There was no linear relationship
between the number of biopsies per patient and
IHPoT index per patient (see Fig. 1). Moreover, our
simulation study showed that the error in calculating
the IHPoT index usingMEMwas very small (close to
zero) regardless of the number of biopsy pieces (see
Fig. S1).
As expected, there was no significant difference
in IHPoT index in the pretreatment biopsy pieces
between surgery patients (median [range] 0.1637
[0–3.17]) and chemo+surgery patients (median
[range] 0.1692 [0–2.69],P= 0.43). Therewas no signif-
icant difference in clinicopathological characteristics
comparing patients with low or high IHPoT index in
each treatment group, with the exception of tumor
location in the chemo+surgery patients (Table 1). In
particular, there was no difference by histological EC
subtype.
Intratumoral heterogeneity of the proportion of tumor
and survival
Chemo+surgery patients with low IHPoT index in the
pretreatment biopsy had a significantly longer sur-
vival compared to surgery patients with low IHPoT
index in univariate analysis (HR = 1.81, 95% CI:
1.20–2.75,P= 0.005 [Fig. 2]) and inmultivariate anal-
ysis (HR= 1.9, 95% CI: 1.24–2.98, P= 0.003).
There was no significant difference in survival
when comparing chemo+surgery patients with high
IHPoT index in the pretreatment biopsy to surgery
patients with high IHPoT index (HR= 1.15, 95% CI:
0.72–1.81, P= 0.566 [Fig. 2]).
As we previously found that patients with a mean
absolute biopsy PoT value between 40% and 70% had
a survival benefit from preoperative chemotherapy,
we additionally explored whether the improved OS
in this particular patient subgroup is related to
the degree of intratumor heterogeneity of PoT. In
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Table 1 Patient characteristics according to intratumoral heterogeneity of the proportion of tumor index in each treatment arm
Chemotherapy + surgery Surgery alone
Low IHPoT n (%) High IHPoT n (%) P-value Low IHPoT n (%) High IHPoT n (%) P-value
Age (years)
≤65 32 (57) 24 (43) 0.477 39 (57) 29 (43) 0.883
>65 22 (50) 22 (50) 28 (56) 22 (44)
Gender
Female 10 (46) 12 (56) 0.363 17 (50.0) 17 (50.0) 0.344
Male 4 4(56) 34 (44) 50 (59.5) 34 (40.5)
Depth of invasion ((y)pT)∗
T0/Tis 2 (67) 1 (33) 0.055 0 0 0.353
T1 3 (33) 6 (67) 6 (50) 6 (50)
T2 9 (82) 2 (18) 5 (83) 1 (17)
T3 33 (57) 25 (43) 42 (58) 30 (42)
T4 0 3 (100) 0 1 (100)
Lymph node status ((y)pN)∗
N0 20 (51) 19 (49) 0.422 20 (59) 14 (41) 0.985
N1 27 (60) 18 (40) 34 (59) 24 (41)
(y)pTNM stage∗
0 2 (67) 1 (33) 0.706 0 0 0.361
I 2 (33) 4 (67) 4 (44) 5 (56)
II 19 (56) 15 (44) 21 (68) 10 (32)
III 24 (59) 17 (42) 28 (55) 23 (45)
Mandard tumor regression grade
1 2 (67) 1 (33) 0.788 Not applicable
2 1 (50) 1 (50)
3 7 (70) 3 (30)
4 13 (48) 14 (52)
5 24 (59) 17 (42)
Histological tumor type
Squamous cell
carcinoma
11 (50) 11 (50) 0.791 10 (46) 12 (55) 0.346
Adenocarcinoma 33 (57) 25 (43) 41 (62) 25 (38)
others 1 (100) 0 2 (67) 1 (33)
Resection margin status
Positive 14 (50) 14 (50) 0.661 20 (61) 13 (39) 0.629
Negative 33 (55) 27 (45) 31 (55) 25 (45)
Tumor location
Lower 31 (46) 36 (54) 0.010 50 (62) 31 (38) 0.256
Middle 12 (57) 9 (43) 12 (46) 14 (53)
Upper 11 (92) 1 (8) 5 (46) 6 (43)
IHPoT, intratumoral heterogeneity of the proportion of tumor.∗No data is available for patients who did not proceed to surgery, n= 43.
chemo+surgery and surgery patients, 84 (55.6%)
patients with a mean absolute biopsy PoT value
between 40% and 70% had a low IHPoT index
compared to 67 (44.4%) patients with mean absolute
PoT values <40% or >70%, P= 0.956. The survival
benefit from preoperative chemotherapy seemed to
be even higher in the subgroup of chemo+surgery
patients with a mean absolute biopsy PoT value
between 40% and 70% and low IHPoT index (n= 36,
HR= 2.71, 95%CI: 1.60–4.61, P< 0.001 [Fig. 2]),
which has been also confirmed by multivariate
analysis (HR= 3.13, 95% CI: 1.77–5.55, P< 0.001).
In contrast, patients with a mean absolute biopsy PoT
value between 40% and 70% and high IHPoT index
did not have a survival benefit from chemotherapy
(Fig. 2). In exploratory analysis, patients with mean
absolute PoT <40% or >70% did not seem to have
a survival benefit from chemotherapy irrespective of
the IHPoT index (Fig. S2).
There was neither a significant difference in
survival of surgery patients comparing high versus
low IHPoT index (HR= 0.76, 95% CI: 0.50–1.15,
P= 0.19) nor within the chemo+surgery patients
(HR= 1.19, 95% CI: 0.75–1.90, P= 0.45) [Fig. 3].
DISCUSSION
This is the first study to measure intratumoral hetero-
geneity of the proportion of tumor (IHPoT) in routine
hematoxylin/eosin stained pretreatment endoscopic
biopsies from esophageal cancer (EC) patients from
the randomized UK MRC OE02 trial. We used a
mixed effect model (MEM) to estimate the IHPoT
level by modeling the probability of being tumor for
each measurement point in the biopsy pieces.
In this exploratory, hypothesis-generating study
using a MEM, we found that patients with a low
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Fig. 2 Five-year overall survival of patients treated with chemotherapy plus surgery versus surgery alone stratified by intratumoral
heterogeneity of the proportion of tumor (IHPoT) index and mean absolute PoT value. (A) Patients with low IHPoT index (<0.2030):
chemo+surgery patients survived significantly longer than surgery patients (HR= 1.81, 95% CI: 1.20–2.75, P= 0.005). (B) Patients with
high IHPoT index (>0.2030): there is no significant difference in survival between chemo+surgery patients and surgery patients (HR= 1.15,
95% CI: 0.72–1.81, P= 0.566). (C) Patients with low IHPoT index and 40%≤PoT≤ 70%: chemo+surgery patients survived significantly
longer than surgery patients (HR= 2.71, 95% CI: 1.60–4.61, P< 0.001). (D) Patients with high IHPoT index and 40%≤PoT≤ 70%: there
is no significant difference in survival between chemo+surgery patients and surgery patients (HR= 1.52, 95%CI: 0.85–2.70, P< 0.153).
IHPoT index in the pretreatment biopsy (e.g. the
proportion of tumor per biopsy piece from the same
patient was very similar) had a survival benefit
from cytotoxic chemotherapy. We have previously
shown that patients with a mean absolute PoT of
40%≤PoT≤ 70% had a survival benefit from pre-
operative chemotherapy.7 We can now demonstrate
that patients with tumors with a mean absolute PoT
value between 40% and 70% and low IHPoT index
at the same time had the most survival benefit from
preoperative chemotherapy. In contrast, patients with
a high IHPoT index (e.g. large variation in the PoT
values between biopsy pieces) derived little or no
survival benefit from chemotherapy.
Recently, image analysis of hematoxylin/eosin
stained sections from lung cancer was found to be
predictive of mutation status,17 providing evidence
that the morphological phenotype of the tumor is
reflective of its molecular phenotype. Studies in
esophageal, head and neck, and colon cancer have
investigated ‘molecular intratumoral heterogene-
ity’ without providing a definition for intratumor
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Fig. 3 Five-year overall survival of patients with high versus low intratumoral heterogeneity of the proportion of tumor (IHPoT) index
within each treatment group. (A) There is no significant difference between the survival of surgery patients with high IHPoT index versus
low IHPoT index (HR= 0.76, 95% CI: 0.50–1.15, P= 0.19). (B) There is no significant difference between the survival of chemo+surgery
patients with high IHPoT index versus low IHPoT index (HR= 1.19, 95% CI: 0.75–1.90, P= 0.45).
heterogeneity as such. Existing data relating to
‘intratumoral heterogeneity’ are therefore difficult to
interpret and cannot be compared with each other or
with our current study which investigated histological
intratumoral heterogeneity.18–27.
‘Genetic heterogeneity’ in cancer at the mutational
or copy number level has been suggested to influence
response to cytotoxic chemotherapy.28 In a study of
8 EC patients, multiregion exome sequencing showed
that ‘intratumor genetic heterogeneity’ is associated
with a poor response to neoadjuvant chemotherapy.29
These results appear to be consistent with our his-
tology based study on a larger series of randomized
clinical trial patients, including a control group of
patients treated by surgery alone.
To the best of our knowledge, this is the first
study that has used a statistical method to objectively
measure and clearly define intratumor heterogeneity.
Results of our study suggest that intratumoral
heterogeneity of the relative tumor content per tissue
area is a potential useful biomarker for clinical
decision making in esophageal cancer patients. Based
on the results of our simulation study, we propose
that the minimum number of biopsy pieces required
to measure IHPoT index is 2. As implementation
of MEM for IHPoT index reporting in routine
pathology might not be feasible, future studies should
determine whether IHPoT in EC biopsies can be
reliably estimated by pathologists.
Limitations of our study include that this is a
retrospective ad hoc analysis of a subset of available
pretreatment biopsies from OE02 trial patients
containing two or more tumor-containing biopsy
pieces. In our study, we measured intratumoral
heterogeneity between biopsy pieces from the same
patient. Intratumoral heterogeneity within individual
biopsy pieces was not considered but may have an
influence on our results. It was unfeasible to perform
multivariate analyses, including known prognostic
factors such as depth of invasion and lymph node
status, for two reasons. Firstly, detailed pretreatment
staging data were not collected in this trial.8 Secondly,
using the pathological stage derived after surgery
may not be representative of the stage in the biopsies
from patients treatedwith neoadjuvant chemotherapy
due to chemotherapy induced pathological changes.
It was also not feasible to perform analyses based
on histological subtype due to small sample size
and a lack of statistical power. Furthermore, it is
not clinically relevant since patients with esophageal
squamous cell carcinoma and adenocarcinoma
receive the same treatment.
CONCLUSIONS
In the era of whole genome sequencing and next
generation sequencing, the increasing complexity of
intratumoral heterogeneity in cancer is becoming evi-
dent. However, the predictive value of molecular het-
erogeneity in response to therapy remains to be clari-
fied and has not been implemented into clinical rou-
tine. We have shown that estimating intratumoral het-
erogeneity of a histological factor such as proportion
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of tumor using digitized hematoxylin/eosin stained
pretreatment biopsy slides and amixed effect model is
predictive of survival benefit to cytotoxic chemother-
apy in EC patients from the Oe02 trial and may repre-
sent a clinically useful biomarker for patient treatment
stratification.
SUPPLEMENTARY DATA
Supplementary data mentioned in the text are avail-
able to subscribers in DOTESO online.
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